MSD launched Ontruzant, Europe's first biosimilar to Roche Holding's Herceptin, or trastuzumab, in the UK. The breast cancer treatment biosimilar was developed by Samsung Bioepsis.
Europe gains first biosimilar to breast cancer drug Herceptin
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.